Loading
gp100 is a pigment-cell protein, and the target of the first bispecific drug to improve survival in a solid tumour, uveal melanoma. This dossier gathers the 1 product (1 approved), 3 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Melanosomal matrix protein; intracellular, presented on HLA.
| Modality | Approved |
|---|---|
| T-cell engager 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Recruiting | Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM) | - | ||
IMCgp100-202 NCT03070392 | 2 | Positive | Untreated HLA-A*02:01-positive metastatic uveal melanoma: tebentafusp vs investigator's choice (pembrolizumab, ipilimumab, or dacarbazine) | OS 21.7 vs 16.0 months; HR 0.51. | |
| 1/2 | Active | Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"gp100" OR ABSTRACT:"gp100" OR TITLE:"PMEL" OR ABSTRACT:"PMEL") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about gp100 (PMEL), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/gp100.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/gp100.json. Licence CC BY-NC 4.0.